An Open-label Safety, Tolerability and Dose-range Finding Study of Multiple Doses of ISIS SMNRx in Patient With Spinal Muscular Atrophy (SMNRx - CS2)

This study has been completed.
Information provided by (Responsible Party):
Isis Pharmaceuticals Identifier:
First received: October 8, 2012
Last updated: March 9, 2015
Last verified: March 2015
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: January 2015
  Primary Completion Date: January 2015 (Final data collection date for primary outcome measure)